Xintela AB (publ) announces that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company's patent application covering targeted antibody treatment of tumors of the central nervous system (CNS). Xintelas patent application 15/550,837 in the USA protects the use of the target molecule integrin 101 for antibody based treatment of tumors of the CNS, including glioblastoma. Xintela has now received a Notice of Allowance which means that the USPTO intends to grant the patent after completion of certain formal steps. Once granted, the patent can be kept in force until 2036. The corresponding European patent application was recently granted by the European Patent Office (EPO). Xintela has previously reported that the company's ADC (Antibody-Drug Conjugate) antibodies have the capability to kill glioblastoma cells, both in cell based studies and in an animal model. The results have been published in the journal Cancers (2019, Vol. 11, p. 587). Additionally, in December 2019, Xintela announced that the company's function-blocking antibodies have demonstrated an inhibitory effect on glioblastoma tumor growth in a preclinical study.